Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation |
Byung Kook Kim, M.D., So Young Kwon, M.D., Soon-Young Ko, M.D.,
Won Hyeok Choe, M.D., Chang Hong Lee, M.D., He-Seong Han, M.D.1,
Seong-Hwan Chang, M.D.2 |
Department of Internal Medicine, 1Department of Pathology and 2Department of Surgery, Konkuk University School of Medicine, Seoul, Korea |
|
|
|
ABSTRACT |
|
Fibrosing cholestatic hepatitis (FCH) is the most devastating manifestation of recurrent hepatitis C in transplant recipients with hepatitis C virus (HCV), possibly leading to death or retransplantation. Although FCH was first described as a complication of hepatitis B, this manifestation has been well documented in association with HCV in the setting of liver transplantation, bone marrow transplantation, heart transplantation, and end-stage human immunodeficiency virus infection. We report the clinical course and antiviral response in a patient with FCH due to recurrent hepatitis C after cadaveric liver transplantation who was treated with pegylated interferon α-2a and ribavirin. (Korean J Hepatol 2008;14:519-524) |
KeyWords:
Hepatitis C; Liver Transplantation; Cholestasis; Fibrosis |
|
|